In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? - PubMed (original) (raw)
Review
In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?
S Schaller et al. Assay Drug Dev Technol. 2005 Oct.
Abstract
Although our approach to the clinical management of osteoporosis (OP) and degenerative joint diseases (DJD)-major causes of disability and morbidity in the elderly-has greatly advanced in the past decades, curative treatments that could bring ultimate solutions have yet to be found or developed. Effective and timely development of candidate drugs is a critical function of the availability of sensitive and accurate methodological arsenal enabling the recognition and quantification of pharmacodynamic effects. The established concept that both OP and DJD arise from an imbalance in processes of tissue formation and degradation draws attention to need of establishing in vitro, ex vivo, and in vivo experimental settings, which allow obtaining insights into the mechanisms driving increased bone and cartilage degradation at cellular, organ, and organism levels. When addressing changes in bone or cartilage turnover at the organ or organism level, monitoring tools adequately reflecting the outcome of tissue homeostasis become particularly critical. In this context, bioassays targeting the quantification of various degradation and formation products of bone and cartilage matrix elements represent a useful approach. In this review, a comprehensive overview of widely used and recently established in vitro, ex vivo, and in vivo set-ups is provided, which in many cases effectively take advantage of the potentials of biomarkers. In addition to describing and discussing the advantages and limitations of each assay and their methods of evaluation, we added experimental and clinical data illustrating the utility of biomarkers for these methodological approaches.
Similar articles
- Subchondral bone as a key target for osteoarthritis treatment.
Castañeda S, Roman-Blas JA, Largo R, Herrero-Beaumont G. Castañeda S, et al. Biochem Pharmacol. 2012 Feb 1;83(3):315-23. doi: 10.1016/j.bcp.2011.09.018. Epub 2011 Sep 22. Biochem Pharmacol. 2012. PMID: 21964345 Review. - Biochemical markers in osteoarthritis with lessons learned from osteoporosis.
Karsdal MA, Henriksen K, Bay-Jensen AC. Karsdal MA, et al. Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):73-87. Epub 2019 Oct 15. Clin Exp Rheumatol. 2019. PMID: 31621570 Review. - Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review.
Sumer EU, Schaller S, Sondergaard BC, Tankó LB, Qvist P. Sumer EU, et al. Biomarkers. 2006 Nov-Dec;11(6):485-506. doi: 10.1080/13547500600886115. Biomarkers. 2006. PMID: 17056470 Review. - The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
Yasuda Y, Kaleta J, Brömme D. Yasuda Y, et al. Adv Drug Deliv Rev. 2005 May 25;57(7):973-93. doi: 10.1016/j.addr.2004.12.013. Epub 2005 Apr 15. Adv Drug Deliv Rev. 2005. PMID: 15876399 Review. - DOTAM derivatives as active cartilage-targeting drug carriers for the treatment of osteoarthritis.
Hu HY, Lim NH, Ding-Pfennigdorff D, Saas J, Wendt KU, Ritzeler O, Nagase H, Plettenburg O, Schultz C, Nazare M. Hu HY, et al. Bioconjug Chem. 2015 Mar 18;26(3):383-8. doi: 10.1021/bc500557s. Epub 2015 Feb 12. Bioconjug Chem. 2015. PMID: 25629889
Cited by
- The Role of Synovial Membrane in the Development of a Potential In Vitro Model of Osteoarthritis.
Harvanova D, Matejova J, Slovinska L, Lacko M, Gulova S, Fecskeova LK, Janockova J, Spakova T, Rosocha J. Harvanova D, et al. Int J Mol Sci. 2022 Feb 24;23(5):2475. doi: 10.3390/ijms23052475. Int J Mol Sci. 2022. PMID: 35269618 Free PMC article. - Ex vivo Bone Models and Their Potential in Preclinical Evaluation.
Cramer EEA, Ito K, Hofmann S. Cramer EEA, et al. Curr Osteoporos Rep. 2021 Feb;19(1):75-87. doi: 10.1007/s11914-020-00649-5. Epub 2021 Jan 11. Curr Osteoporos Rep. 2021. PMID: 33428030 Free PMC article. Review. - Bone Turnover Markers and Probable Advanced Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Men and Postmenopausal Women With Type 2 Diabetes.
Wang N, Wang Y, Chen X, Zhang W, Chen Y, Xia F, Wan H, Li Q, Jiang B, Hu B, Lu Y. Wang N, et al. Front Endocrinol (Lausanne). 2020 Jan 28;10:926. doi: 10.3389/fendo.2019.00926. eCollection 2019. Front Endocrinol (Lausanne). 2020. PMID: 32063885 Free PMC article. - Extracellular matrix turnover and inflammation in chemically-induced TMJ arthritis mouse models.
Morel M, Ruscitto A, Pylawka S, Reeve G, Embree MC. Morel M, et al. PLoS One. 2019 Oct 11;14(10):e0223244. doi: 10.1371/journal.pone.0223244. eCollection 2019. PLoS One. 2019. PMID: 31603905 Free PMC article. - GPDPLQ1237-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro.
Löfvall H, Katri A, Dąbrowska A, Karsdal MA, Luo Y, He Y, Manon-Jensen T, Dziegiel MH, Bay-Jensen AC, Thudium CS, Henriksen K. Löfvall H, et al. Sci Rep. 2019 Feb 28;9(1):3050. doi: 10.1038/s41598-019-39803-0. Sci Rep. 2019. PMID: 30816326 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous